

## IN THE CLAIMS

Claims 1 - 34 (Canceled)

Claim 35. (Currently Amended) A composition for generating an immune response to a prostate tumor-associated antigen, comprising:

a proliferation-incompetent cell comprising a nucleic acid encoding said prostate tumor-associated antigen, wherein when said prostate tumor-associated antigen is expressed, said antigen stimulates a humoral response when provided on a by said proliferation-incompetent cell in the presence of GM-CSF, and does not stimulate a humoral immune response when provided is detected, said humoral immune response not detected when said prostate tumor-associated antigen is expressed by said proliferation-incompetent cell in the absence of GM-CSF; and wherein said prostate tumor-associated antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as determined by SDS-PAGE, and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

Claim 36. (Previously Presented) The composition of Claim 35, wherein said proliferation-incompetent cell is autologous.

Claim 37. (Previously Presented) The composition of Claim 35, wherein said proliferation-incompetent cell is allogeneic.

Claim 38. (Currently Amended) The composition of Claim 35, wherein said GM-CSF is expressed by ~~a second non-cancerous~~ the same cell that expresses said prostate tumor-associated antigen.

Claim 39. (Currently Amended) The composition of Claim 35, wherein said prostate tumor-associated antigen has a molecular weight of 250 kD.

Claim 40. (Previously Presented) The composition of Claim 35, wherein said

proliferation-incompetent cell is a prostate cell.

Claim 41. (Currently Amended) The composition of Claim 35, further comprising a host cell, wherein said prostate tumor-associated antigen is expressed ~~at the surface of~~ by said host cell.

Claim 42. (Currently Amended) The composition of Claim 35, ~~further comprising a second cell comprising a nucleic acid encoding a~~ wherein said GM-CSF expressing cell is non-cancerous.

Claim 43. (New) The composition of Claim 35, wherein said GM-CSF is expressed by a different cell than the cell expresses said prostate tumor-associated antigen.